
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals PLC is advancing its Orexin Receptor 2 Agonist Program and LockBody Technology Platform, focusing on small molecule therapeutics aimed at addressing various neuroscience diseases related to the orexin pathway. With preliminary data indicating best-in-class efficacy for ORX750 and expectations for additional supportive data by 1Q26, the company has a projected sales potential of approximately $3.6 billion, highlighting significant upside for investors. Management's comments on the drug's safety profile and the potential for optimized dosing strategies further enhance the positive outlook for Centessa Pharmaceuticals and its pipeline.
Bears say
The outlook for Centessa Pharmaceuticals's stock is negatively influenced by multiple fundamental factors, including regulatory uncertainties regarding acquisition completions and potential setbacks affecting key drug candidates, cleminorexton and ORX142. Additionally, high non-responder rates and late-day waning efficacy observed in clinical trials raise concerns about the overall viability of the orexin receptor 2 agonist class, indicating possible fundamental limitations in both dose selection and administration compliance. Furthermore, the complexity introduced by variability in Phase 2 trial results, coupled with increasing competitive pressures in the market, further compounds the challenges facing Centessa’s development pipeline, potentially impacting future financial performance.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares